{
  "id": 10386959,
  "title": "4basebio reports 210% rise in H1 sales orders amid revenue decline",
  "url": "https://urgent.news/2026/09/28/4basebio-reports-210-rise-in-h1-sales-orders-amid-revenue-decline",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-28T06:42:29.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/4basebio-reports-210-rise-in-h1-sales-orders-amid-revenue-decline-93CH-4919407"
  },
  "original_language": "en",
  "account": "4basebio PLC, a synthetic DNA manufacturer for genomic medicines based in Cambridge, UK, reported a substantial 210% increase in sales orders for the first half of 2026 compared to the same period last year, with orders totaling £1.2 million. However, revenue for the period fell to £0.3 million from £1.2 million in H1 2025, primarily due to project delays caused by market headwinds and a significant contract from a large clinical pharmaceutical. The company reported a loss of £8.9 million for H1 2026, up from £7.8 million in the previous period, while cash outflow from operations increased to £8.4 million, up from £8.2 million. Cash reserves were £14.1 million at the end of the period, down from £17.8 million at the end of 2025, and the company drew on a loan facility of €7 million provided by 2Invest AG to extend its cash runway into late 2027. Despite the revenue decline, 4basebio still has a qualified business pipeline worth £63 million, which has increased six-fold since Q3 2025. The company has secured a clinical supply agreement for a Phase 2 clinical trial and signed a collaboration with Genezen, a viral vector contract development and manufacturing organization. Additionally, 4basebio extended an existing relationship with a pharmaceutical customer to support a Phase 1 cell therapy program and launched new product offerings, including a single-stranded DNA platform and personalized cancer vaccines.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}